An investigation on the relationship between the occurrence of CMV DNAemia and the development of invasive aspergillosis in the allogeneic stem cell transplantation setting

Journal of Medical Virology

Volumn 86, Issue 4, 2014, Pages 568-575

  Giménez, Estela ^a   Solano, Carlos ^a,b   Nieto, José ^c   Remigia, María José ^a   Clari, María Ángeles ^a   Costa, Elisa ^a   Muñoz Cobo, Beatriz ^a   Amat, Paula ^a   Bravo, Dayana ^a   Benet, Isabel ^a   Navarro, David ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

CMV DNAemia; CMV end organ disease; Cytomegalovirus; Invasive aspergillosis; Serum galactomannan

Indexed keywords

CMV DNAEMIA; CMV END-ORGAN DISEASE; CYTOMEGALOVIRUS; INVASIVE ASPERGILLOSIS; SERUM GALACTOMANNAN;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; ITRACONAZOLE; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PYRIMIDINES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SUPERINFECTION; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 84893751745     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23735     Document Type: Article

References (23)

1. Blanquer J, Chilet M, Benet I, Aguilar G, Muñoz-Cobo B, Tellez A, Costa E, Bravo D, Navarro D. 2011. Immunological insights into the pathogenesis of active CMV infection in non-immunosuppressed critically ill patients. J Med Virol 83:1966-1971.
2. Bravo D, Clari MÁ, Costa E, Muñoz-Cobo B, Solano C, José Remigia M, Navarro D. 2011. Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantitation of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. J Clin Microbiol 49:2899-2904.
3. Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, Halter J, Heim D, Tichelli A, Gratwohl A, Stern M. 2010. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 16:1309-1314.
4. Chilet M, Aguilar G, Benet I, Belda J, Tormo N, Carbonell JA, Clari MA, Costa E, Navarro D. 2010. Virological and immunological features of active cytomegalovirus infection in nonimmunosuppressed patients in a surgical and trauma intensive care unit. J Med Virol 82:1384-1391.
5. Cook CH, Zhang Y, McGuiness BJ, Lahm MC, Sedmak DD, Ferguson RM. 2002. Intra-abdominal infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis 185:1395-1400.
6. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. 2008. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the National Institute of allergy and infectious diseases Mycoses study group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821.
7. Freeman RB. 2009. The "indirect effects" of cytomegalovirus infection. Am J Transplant 9:2453-2458.
8. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Martin PJ, Storb RF, Marr KA. 2003. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102:827-833.
9. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. 2008. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantation. Clin Infect Dis 47:1041-1050.
10. Gimeno C, Solano C, Latorre JC, Hernández-Boluda JC, Clari MA, Remigia MJ, Furió S, Calabuig M, Tormo N, Navarro D. 2008. Quantification of DNA in plasma by an automated real-time PCR assay (CMV PCR Kit, Abbott) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 46:3311-3318.
11. Grow WB, Moreb JS, Roque D, Manion K, Leather H, Reddy V, Khan SA, Finiewicz KJ, Nguyen H, Clancy CJ, Mehta PS, Wingard JR. 2002. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 29:15-19.
12. Hamilton JR, Overall JC, Jr. Glasgow LA. 1977. Synergistic infection with murine cytomegalovirus and Candida albicans in mice. J Infect Dis 135:918-924.
13. Ibrahim A, Gautier E, Roittmann S, Bourhis JH, Fajac A, Charnoz I, Terrier P, Salord JM, Tancrède C, Hayat M, Bernaudin JF, Pico JL. 1997. Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation? Br J Haematol 98:222-227.
14. Kamar N, Mengelle C, Rostaing L. 2007. Alteration of direct and indirect effects ofcytomegalovirus. Exp Clin Transplant 5:727-730.
15. Ljungman P, Griffiths P, Paya C. 2002. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34:1094-1097.
16. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 100:4358-4366.
17. Martino R, Subirá M, Rovira M, Solano C, Vázquez L, Sanz GF, Urbano-Ispizua A, Brunet S, De la Cámara R. 2002. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: Incidence and risk factors in 395 patients. Br J Haematol 116:475-482.
18. Mikulska M, Raiola AM, Bruno B, Furfaro E, Van Lint MT, Bregante S, Ibatici A, Del Bono V, Bacigalupo A, Viscoli C. 2009. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: An analysis of 306 patients. Bone Marrow Transplant 44:361-370.
19. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. 2002. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 185:273-282.
20. Solano C, Navarro D. 2010. Clinical virology of cytomegalovirus infection following hematopoietic transplantation. Future Virol 5:111-124.
21. Tormo N, Solano C, Benet I, Nieto J, de la Cámara R, López J, Garcia-Noblejas A, Muñoz-Cobo B, Costa E, Clari MA, Hernández-Boluda JC, Remigia MJ, Navarro D. 2011. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. Bone Marrow Transplant 46:1437-1443.
22. Wang LR, Dong LJ, Zhang MJ, Lu DP. 2008. Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 42:673-677.
23. Zaia JA, Schmidt GM, Chao NJ, Rizk NW, Nademanee AP, Niland JC, Horak DA, Lee J, Gallez-Hawkins G, Kusnierz-Glaz CR. 1995. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: Long-term follow-up. Biol Blood Marrow Transplant 1:88-93.